| 1. |
Cost, not adherence, main barrier to antiretroviral treatment in Africa |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1452,
2004,
Page 2-2
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 2. |
Bupropion prescribing cautious in Ireland |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1452,
2004,
Page 3-3
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 3. |
Ciclosporin monitoring: 2-hour post-dose strategy cost saving |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1452,
2004,
Page 4-4
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 4. |
QOL improves following superior lumiracoxib effect in OA |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1452,
2004,
Page 5-6
L Everitt,
Preview
|
|
摘要:
Osteoarthritis (OA) is a highly prevalent, chronic disease affecting the joints. Stiffness and pain associated with this condition contributes to patients' inability to perform normal activities on a daily basis. Lumiracoxib [Prexige] is a selective and highly potent inhibitor of cyclo-oxygenase (COX)-2 in development by Novartis for the treatment of OA, acute pain and rheumatoid arthritis. At the Annual European Congress of Rheumatology (EULAR) [Berlin, Germany; June2004], a multinational investigative team presented the results of its multicentre, randomised trial in patients with primary OA, and revealed that lumiracoxib brought about"clinically relevant improvements in the patient's condition".1The results of a second randomised trial presented at the meeting showed that all aspects of QOL improved significantly following treatment with lumiracoxib, compared with placebo.2
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 5. |
Promising findings: FTY 720 may prevent renal transplant rejection |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1452,
2004,
Page 6-6
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 6. |
Fusion cell vaccines feasible in renal and metastatic breast cancer |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1452,
2004,
Page 7-7
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 7. |
Adjuvant androgen suppression improves survival in prostate cancer |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1452,
2004,
Page 8-8
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 8. |
Enfuvirtide-based treatment provides long-term benefit |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1452,
2004,
Page 9-10
Preview
|
|
摘要:
Enfuvirtide [Fuzeon], the first agent in the new class of antiretrovirals called fusion inhibitors, provides durable suppression of HIV and continuous increases in CD4 cells over a 96-week period, and does not appear to be associated with any late-emerging safety issues, according to the latest combined results of the TORO trials presented at the XV International AIDS Conference [Bangkok, Thailand; July 2004]. Over 96 weeks, treatment with enfuvirtide in combination with an optimised background regimen (OB), reduced viral loads to < 400 and < 50 copies/mL in 26% and 17% of patients, respectively. Of those patients randomised to receive enfuvirtide plus OB, 56% remained on treatment at 96 weeks.
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 9. |
Levofloxacin is effective in the treatment of > 90% of patients with Legionella infections, |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1452,
2004,
Page 10-10
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 10. |
Periprocedural dalteparin sodium useful bridging anticoagulation |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1452,
2004,
Page 11-11
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
首页
